Congressional Research Service Reports - 555 Matching Results

Search Results

prev Results: 501 - 550 next
Importing Prescription Drugs
No Description Available.
Importing Prescription Drugs
No Description Available.
Medicare: Major Prescription Drug Provisions of Selected Bills
No Description Available.
Medicare: Major Prescription Drug Provisions of Selected Bills
No Description Available.
Medicare: Major Prescription Drug Provisions of Selected Bills
No Description Available.
President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
No Description Available.
President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
No Description Available.
President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
No Description Available.
The Cost of Prescription Drugs for the Uninsured Elderly and Legislative Approaches
The purpose of this report is to explain why many of those who are least able to afford high drug costs are those who are most frequently charged the most. This report describes the basic economic theory underlying price differentiation and, in the context of the pharmaceutical market, analyzes the role and behavior of pharmacy benefit managers (PBMs), pharmaceutical manufacturers, and retail pharmacies, respectively. It also looks at a number of the criticisms that have been made of the practice of differential pricing. Finally, this report discusses various policy approaches aimed at assisting the elderly to purchase prescription drugs.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on the Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
The Hatch-Waxman Act: Proposed Legislative Changes
No Description Available.
Prescription Drug User Fee Act of 1992: Effects on Bringing New Drugs to Market
No Description Available.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Tobacco Advertising: Whether the FDA's Restrictions Violate Freedom of Speech
No Description Available.
Tobacco Master Settlement Agreement (1998): Overview, Implementation by States, and Congressional Issues
On November 23, 1998, attorneys general representing 46 states, the District of Columbia, and the five U.S. territories signed an agreement with the major cigarette companies to settle all the state lawsuits seeking to recover the Medicaid costs of treating smokers. The Master Settlement Agreement, or MSA, contractually imposes some restrictions on tobacco advertising, marketing, and promotion and requires the manufacturers to make annual payments totaling about $206 billion through 2025. It follows earlier individual settlements with four states--Mississippi, Florida, Texas, and Minnesota--totaling more than $40 billion over the first 25 years. Cigarette price increases have passed on those settlement costs to smokers.
The Tobacco Settlement: Issues
Since 1994, 41 states and Puerto Rico have sued the tobacco industry to recover the medical costs of treating smokers. On June 20, 1997, a group of state attorneys general and industry lawyers announced that they had reached a settlement that would protect the tobacco companies from civil liability in return for annual industry payments of $365.5 billion over 25 years to reimburse states for their tobacco-related medical costs, and pay for tobacco control programs to reduce tobacco use among teenagers.
Compensating Farmers for the Tobacco Settlement
The legislative proposals designed to reduce smoking, primarily by teenagers, are likely to have negative economic consequences for tobacco growers and tobacco-dependent communities. This report discusses the possibility of some kind of compensation to farmers as part of the settlement package legislation.
The Proposed Tobacco Settlement: Effects on Prices, Smoking Behavior, and Income Distribution
No Description Available.
The Tobacco Settlement: An Overview
On June 20, a group of state attorneys general, plaintiffs' lawyers, public health advocates, and lawyers representing cigarette manufacturers announced an historic settlement that would restructure the tobacco industry and revolutionize the nation's tobacco control efforts. The proposed settlement is currently under congressional consideration, and would require legislation and the President's approval before taking effect
The Proposed Tobacco Settlement: Who Pays for the Health Costs of Smoking?
No Description Available.
Summary and Comparison of the Major Agricultural Provisions of the Tobacco Settlement Policy Proposals
No Description Available.
Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship
Interest in methods to provide drugs at lower cost, particularly for the elderly, has rekindled discussion over the role the federal government plays in facilitating the creation of new pharmaceuticals for the marketplace. This report explores the issue of whether or not the substantial federal investment in health-related research and development (R&D) entitles the public to commensurate consideration in prices charged for any resulting drugs. It is intended to provide the reader with an understanding of the rationale for government support of R&D and subsequent efforts to facilitate private sector commercialization of new technologies generated from such work. Concerns surrounding innovation in pharmaceuticals and biotechnology are discussed within the broader context of the federal role in facilitating technological progress.
Tobacco Control: Enforcement and Effectiveness of Federal and State Youth Access Laws
This report reviews recent efforts to limit youth access to cigarettes through enforcement of federal and state laws prohibiting tobacco sales to minors. Under the federal Synar Amendment, states must conduct compliance checks and enforce their minimum age-of-sale laws or risk losing block grant funds
Tobacco Legislation in the 105th Congress: Side-by-Side Comparison of S. 1415, S. 1530, S. 1638, S. 1889, H.R. 3474, and H.R. 3868
No Description Available.
Tobacco Marketing and Advertising Restrictions in S. 1415, 105th Congress: First Amendment Issues
No Description Available.
Tobacco Issues: National Public Opinion
No Description Available.
Tobacco Marketing and Advertising Restrictions in S. 1648, 105th Congress: First Amendment Issues
No Description Available.
Tobacco Advertising: The Constitutionality of Limiting its Tax Deductibility
No Description Available.
Tobacco-Related Activities and Programs in the Federal Government: A Summary
No Description Available.
Tobacco-Related Programs and Activities of the U.S. Department of Agriculture: Operation and Cost
The U.S. Department of Agriculture (USDA) has long operated programs that directly assist farmers and others with the production and marketing of numerous crops, including tobacco. In most cases, the programs themselves are not controversial. Increasingly, however, where tobacco is involved, the use of federal funds is being called into question.
Tobacco Price Support: An Overview of the Program
No Description Available.
Tobacco Price Support: An Overview of the Program
Over 93% of U.S. tobacco production is flue-cured and burley (both being cigarette tobacco types). These crops are particularly important to the agriculture of North Carolina (where flue-cured is grown) and Kentucky (where burley is grown). Together, these two states produce 65% of the total U.S. tobacco crop. The federal tobacco price support program is designed to support and stabilize prices for farmers. It operates through a combination of mandatory marketing quotas and nonrecourse loans. Marketing quotas limit the amount of tobacco each farmer can sell, which indirectly raises market prices. The loan program establishes guaranteed minimum prices. The law requires that the loan program operate at no net cost to the federal government. Apart from year-to-year budget impacts, no-net-cost provisions of the law are intended to assure that all loan principal plus interest will be recovered
Medicare's Skilled Nursing Facility Benefit
No Description Available.
Medicare Prescription Drug Provisions of S.1, as Passed by the Senate, and H.R. 1, as Passed by the House
This report discusses differences in the specifics of the prescription drug provisions in S. 1 and H.R. 1 and provides a side-by-side comparison of the Title I provisions of both bills.
Overview of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003
No Description Available.
Overview of the Medicare Prescription Drug and Reform Legislation
No Description Available.
Medicare Prescription Drug and Reform Legislation
This report describes the major features of S. 1, as ordered reported, and the measure to be considered by the House Ways and Means Committee, H.R. 2473, as ordered reported.
Medicare: Beneficiary Cost-Sharing Under Proposed Prescription Drug Benefits
This report provides background on how the cost-sharing and premium provisions under each bill would affect the amount that a beneficiary pays annually for prescription drugs. In addition, this report gives examples of how annual cost-sharing would differ for beneficiaries with various levels of total prescription drug spending in 2006 under the plans.
Back to Top of Screen